Transgene SA

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025

27 Jul 2025 23:30:00 By Nasdaq GlobeNewswire

Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director

09 Jul 2025 08:45:00 By Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025

08 Jul 2025 09:00:00 By Nasdaq GlobeNewswire

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

18 Jun 2025 23:00:00 By Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders

12 Jun 2025 23:30:00 By Nasdaq GlobeNewswire

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

02 Jun 2025 23:00:00 By Nasdaq GlobeNewswire

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

01 Jun 2025 10:15:00 By Nasdaq GlobeNewswire

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

22 May 2025 08:45:00 By Nasdaq GlobeNewswire

Transgene's Combined General Meeting of May 15, 2025

15 May 2025 08:45:00 By Nasdaq GlobeNewswire

Transgene Provides Business and Financial Update for Q1 2025

24 Apr 2025 08:45:00 By Nasdaq GlobeNewswire

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025

23 Apr 2025 23:00:00 By Nasdaq GlobeNewswire

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

23 Apr 2025 08:45:00 By Nasdaq GlobeNewswire

Availability of Transgene’s 2024 Universal Registration Document (URD)

10 Apr 2025 11:15:00 By Nasdaq GlobeNewswire

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

01 Apr 2025 08:45:00 By Nasdaq GlobeNewswire

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

27 Mar 2025 09:45:00 By Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

11 Mar 2025 09:45:00 By Nasdaq GlobeNewswire

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

06 Feb 2025 08:45:00 By Nasdaq GlobeNewswire

Transgene to Participate in the Biomed Forum Investor Conference

21 Jan 2025 08:45:00 By Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2025

14 Jan 2025 08:45:00 By Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

07 Jan 2025 09:00:00 By Nasdaq GlobeNewswire